(Adnkronos) - “Siamo in un punto di svolta: noi esperti della demenza e della malattia di Alzheimer siamo molto elettrizzati da questo momento storico che stiamo vivendo, in quanto raccogliamo i risultati di ricerche che sono in atto da molti anni”. Sono le parole di Annachiara Cagnin, professoressa associata di Neurologia università di Padova, in occasione del 54° Congresso Sin - Società italiana di neurologia, in svolgimento a Roma fino al 12 novembre.
Category
🗞
NewsTranscript
00:00We are at a turning point. I say this not because I am here today, but because we experts,
00:12let's call ourselves so, of the dementia and Alzheimer's disease, we are very
00:17electrified by this historical moment that we are living, because we collect the
00:22research results that have been in force for many years. But somehow, for a
00:29number of favorable conjunctions, everything has been accelerated in recent months,
00:34I would like to say. And this involves both innovations in the field of diagnosis,
00:39which becomes more and more precise with regard to the neuropathological process
00:44of Alzheimer's disease, so what happens in our brain even before or
00:50near the onset of symptoms, and the ways in which this biological diagnosis
00:57can be made. We are moving towards proximity markers, that is,
01:03they tell us at what stage of evolution we are in terms of the pathological process,
01:09how close we are to the evolution of symptoms, how quickly we will enter the
01:14symptomatic phase. But there are innovations, especially in the type of biomarker
01:21that we could use, and I am referring above all to the possibility that there is,
01:26with a blood sample, a diagnosis as accurate as the one we obtain with
01:31the liqueur. This is what the literature tells us, we will have to further
01:37deepen this field with the analysis of reality in the real world, so we are
01:43a little cautious in saying that it is already available. A banal blood test to
01:49make a diagnosis of Alzheimer's disease, things are not that simple, but it is the
01:53first time that I see such a solid biomarker in practical theory and
02:01easy to use. All this will greatly simplify the selection of
02:07symptomatic or slightly symptomatic patients when they enter my
02:16office and ask for the diagnosis to have a pharmacological treatment
02:22oriented to the modification of the path of the disease. So I must be able to have
02:29simple tools to exclude some patients or to include in a more complex
02:35diagnostic process other selected cases. The drugs are behind the door,
02:42we are talking about monoclonal antibodies for Alzheimer's disease, which
02:46have been authorized and used in the United States, in Korea, in Japan, in
02:52Israel, in the Arab Emirates, recently in England, and which are under
02:57evaluation and re-evaluation, so we are waiting for the results.